Ovarian Cancer | Clinical

Salani Reviews Role of PARP Inhibition in Ovarian Cancer

November 24, 2022

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.